Clinical features of patients
| Controls included in lung tissue studies (n=15) | Controls included in serum studies (n=30) | Controls included in BAL-AM studies (n=15) | Patients with IPF (n=27) | |
| Age (years) | 66 (53–80) | 67 (42–81) | 66 (47–79) | 68 (48–86) |
| Sex (M/F) | 10/5 | 18/12 | 10/5 | 16/11 |
| Smoking | ||||
| Never smoked/smokers | 4/11 | 13/17 | 5/10 | 18/9 |
| Pack-year | 28 (0–30) | 24 (0–30) | 27.5 (0–35) | 30 (0–40) |
| FEV1, % pred | 95 (90–110) | 96 (90–115) | 98 (92–110) | 72 (50–120) |
| FVC, % pred | 96 (90–110) | 98 (90–115) | 99 (90–115) | 74 (43–120) |
| TLC, % pred | 95 (90–105) | 96 (87–110) | 94 (87–105) | 66 (43–90) |
| DLco, % pred | 94 (80–107) | 97 (80–107) | 94 (80–107) | 40.5 (20–63) |
| % Ground Glass | 0 | ND | 0 | 10 (0–50) |
| % Honeycombing | 0 | ND | 0 | 25 (0–60) |
| BAL, %+ | ||||
| Macrophages | 90.2 (72–100) | ND | 96 (75–100) | 79 (48–90) |
| Lymphocytes | 7 (2–10) | ND | 5 (2–9) | 6 (2–19) |
| CD4/CD8 | 1.3 (0.6–2) | ND | 1.2 (0.5–2) | 0.9 (0.1–2) |
| Neutrophils | 1.2 (0.2–4) | ND | 1.1 (0.2–4) | 8 (1–30) |
| Eosinophils | 0.7 (0–1) | ND | 0.6 (0–1) | 3 (0–8) |
| PaO2, mm Hg | 94 (84–100) | 96 (85–100) | 95 (85–100) | 60 (40–85) |
| Steroid (yes/no) | 0/15 | 0/30 | 0/15 | 12/15 |
| Azathioprine (yes/no) | 0/15 | 0/30 | 0/15 | 6/21 |
Steroid/azathioprine is referring to patients who received this treatment at the moment of pulmonary biopsy.
Data are the median (range).
AM, alveolar macrophage; BAL, bronchoalveolar lavage; DLco, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; ND, not determined; pack-year = 1 year smoking 20 cigarettes/day; PaO2, oxygen tension in arterial blood; TLC, total lung capacity; % Ground Glass, % of pulmonary parenchyma with Ground Glass in CT image; % Honeycombing, % of pulmonary parenchyma with honeycombing in CT image; % pred, % predicted.